
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Jasper Therapeutics Inc (JSPR)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: JSPR (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $20.12
1 Year Target Price $20.12
7 | Strong Buy |
4 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.2% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.52M USD | Price to earnings Ratio - | 1Y Target Price 20.12 |
Price to earnings Ratio - | 1Y Target Price 20.12 | ||
Volume (30-day avg) 11 | Beta 2.71 | 52 Weeks Range 2.27 - 26.05 | Updated Date 08/15/2025 |
52 Weeks Range 2.27 - 26.05 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -73.3% | Return on Equity (TTM) -146.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8162029 | Price to Sales(TTM) - |
Enterprise Value 8162029 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.42 | Shares Outstanding 15022100 | Shares Floating 9892753 |
Shares Outstanding 15022100 | Shares Floating 9892753 | ||
Percent Insiders 1.27 | Percent Institutions 84.25 |
Upturn AI SWOT
Jasper Therapeutics Inc
Company Overview
History and Background
Jasper Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of conditioning therapies for hematopoietic stem cell transplantation (HSCT) and gene therapy. It was incorporated in 2019 and went public in 2022 via a SPAC merger. The company aims to improve outcomes for patients undergoing HSCT by reducing toxicity and improving engraftment.
Core Business Areas
- Hematopoietic Stem Cell Transplantation (HSCT) Conditioning: Developing and commercializing therapies to improve HSCT outcomes by reducing toxicity and enhancing engraftment.
- Gene Therapy Conditioning: Exploring the use of their conditioning therapies to enable safer and more effective gene therapy.
Leadership and Structure
The leadership team includes Ronald Martell (CEO), Edwin Stone (Chief Medical Officer), and Jeet Mahal (Chief Financial Officer). The company operates with a focus on research and development, clinical trials, and potential commercialization of its pipeline products.
Top Products and Market Share
Key Offerings
- Busamphan: Busamphan is a myeloconditioning agent, a generic name of a therapeutic used to clear bone marrow to allow the patient's body to accept new stem cells, either from their own cells or from a donor's cells. Market share data is not publicly available. Competitors include Bristol Myers Squibb(BUSULFEX).
- Briquilimab: Briquilimab is Jasper's lead product candidate, a monoclonal antibody targeting c-KIT, designed to enable stem cell transplantations without the need for traditional high-intensity chemotherapy or radiation. Market share data is not yet available as it is still in clinical trials. Competitors may emerge as other conditioning regimens are developed.
Market Dynamics
Industry Overview
The HSCT and gene therapy conditioning market is growing, driven by advancements in these fields and the increasing need for safer and more effective conditioning regimens. There is a trend toward reduced-intensity conditioning to minimize toxicity.
Positioning
Jasper Therapeutics aims to be a leader in HSCT and gene therapy conditioning by developing novel therapies that reduce toxicity and improve outcomes. Their competitive advantage lies in their c-KIT targeting antibody, briquilimab.
Total Addressable Market (TAM)
The TAM for HSCT and gene therapy conditioning is estimated to be in the billions of dollars, growing with the expansion of these therapies. Jasper is positioned to capture a significant share of this market if briquilimab is successful.
Upturn SWOT Analysis
Strengths
- Novel c-KIT targeting antibody (briquilimab)
- Experienced leadership team
- Focus on addressing unmet needs in HSCT and gene therapy
- Strong intellectual property portfolio
Weaknesses
- Clinical trial risks and uncertainties
- Limited financial resources
- Reliance on a single lead product candidate
- Small company size
Opportunities
- Potential for briquilimab to become a standard of care in HSCT conditioning
- Expansion of gene therapy applications
- Partnerships with larger pharmaceutical companies
- Development of additional conditioning therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- BMS (BMY)
- Sanofi (SNY)
- Gilead (GILD)
Competitive Landscape
Jasper Therapeutics faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Jasper's competitive advantage lies in its novel c-KIT targeting antibody, briquilimab, if it proves clinically effective.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancement of briquilimab through clinical trials. Since a clinical-stage company, a rapid increase in stock valuation depends on clinical trial results.
Future Projections: Future growth is dependent on the successful completion of clinical trials, regulatory approvals, and commercialization of briquilimab and other pipeline products. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include enrollment in ongoing clinical trials for briquilimab and exploration of partnerships.
Summary
Jasper Therapeutics is a clinical-stage biopharmaceutical company with a promising lead candidate, briquilimab, targeting a significant unmet need in HSCT and gene therapy conditioning. Its success hinges on positive clinical trial outcomes and securing regulatory approvals, facing inherent risks in drug development. The company needs to carefully manage its financial resources to support its clinical programs and achieve commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q), company press releases, investor presentations, industry reports, analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimations are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jasper Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-09-24 | President, CEO & Director Mr. Ronald A. Martell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://jaspertx.com |
Full time employees 64 | Website https://jaspertx.com |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.